Übersicht – Hepatozelluläres Karzinom: Screening und Diagnostik

Das hepatozelluläre Karzinom ist der häufigste bösartige lebereigene Tumor. Seine Entstehung ist multifaktoriell bedingt. Neuere Daten deuten darauf hin, dass eine gestörte Aktivierung unterschiedlicher Signalwege wie beispielsweise Epidermaler Wachstumsfaktor Rezeptor (EGFR) oder mTOR (Mammalian Target of Rapamycin) an der Tumorenstehung beteiligt ist. Insgesamt ist die molekulare Pathognese des hepatozellulären Karzinoms (HCC) jedoch sehr komplex [1], [2].

• Literatur

• 1 Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatolgy 2008; 48: 1312-1327
• 2 Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006; 6: 674-687
• 3 EASL-EORTC Clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943
• 4 Geier A, Schadde E, Müllhaupt B. Hepatozelluläres Karzinom. Frühdiagnose, Staging und neue Therapieoptionen. MMW Fortschr Med 2012; 154: 63-67
• 5 Bruix J, Sherman M. Management of hepatocellular carcinoma. An update. Hepatology 2011; 53: 1020-1022
• 6 Weiss J, Rau M, Geier A. Non-alcoholic fatty liver disease-epidemiology, clinical course, invstigation and treatment. Dtsch Arztebl Int 2014; 111: 447-452
• 7 Calle EE et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003; 348: 1625-1638
• 8 El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: 460-468
• 9 Forner A, Llovet JM, Bruix J. Hepatocellular Carcinoma. Lancet 2012; 379: 1245-1255
• 10 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). Diagnostik und Therapie des hepatozellulären Karzinoms, Langversion 1.0, AWMF Registrierungsnummer: 032-053OL, leitlinienprogrammonkologie.de/Leitlinien.7.0.html.
• 11 Llovet JM, Burroughs A, Bruix J. Hepatocellular Carcinoma. Lancet 2003; 362: 1907-1917
• 12 Bolondi L. Screeing for hepatocellular carcinoma in cirrhosis. J Hepatol 2003; 39: 1076-1084
• 13 Kim CK, Lim JH, Lee WJ. Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver: accuracy of ultrasonography in transplant patients. J Ultrasound Med 2001; 20: 99-104
• 14 Trinchet JC et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 2011; 54: 1987-1997
• 15 Di Bisceglie AM et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatl 2005; 43: 434-441
• 16 Yamashita T et al. EpCam and alpha-fetoprotein expression defines novel diagnostic subtypes of hepatocellular carcinoma. Cancer Res 2008; 68: 1451-1461
• 17 Villanueva A et al. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 2010; 61: 317-328
• 18 Hoshida Y et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009; 69: 7385-7392
• 19 Pateron D et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994; 20: 65-71
• 20 Koike Y et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001; 91: 561-569
• 21 Marrero JA et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 2003; 37: 1114-1121
• 22 Sterling RK, Jeffers L, Gordon F et al. Clinical utility of AFP-L3% in North American patients with HCV-related cirrhosis. Am J Gastroenterol 2007; 102: 2196-2205
• 23 Wang M, Long RE, Comunale MA et al. Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 2009; 18: 1914-1921
• 24 Bruix J et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430
• 25 Khalili K et al. Optimization of imaging diagnosis of 1-2 cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization. J Hepatol 2011; 54: 723-728
• 26 Kim JE et al. Hypervascular hepatocellular carcinoma 1 cm or smaller in patients with chronic liver disease: characterization with gadoxetic acid-enhanced MRI that includes diffusion weighted imaging. Am J Roentgenol 2011; 196: W758-765
• 27 Schraml C, Kaufmann S, Rempp H et al. Imaging of HCC-current state of the art. Diagnostics 2015; 5: 513-545
• 28 Bundesärztekammer (Hrsg.). Richtlinien zur Organtransplantation gem. § 16 TPG Richtlinie gemäß § 16 Abs. 1 S. 1 Nrn. 2 u. 5 TPG für die Wartelistenführung und Organvermittlung zur Lebertransplantation. Dtsch Arztebl 2016; 113: A-346
• 29 Edge SB et al. AJCC Cancer Staging Handbook. 7th ed New York: Springer; 2010
• 30 Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 2016; 150: 835-853